Printer Friendly

PFIZER RESPONDS TO CALIFORNIA COURT OF APPEAL DECISION

 NEW YORK, Jan. 6 /PRNewswire/ -- Pfizer (NYSE: PFE) said today that it will seek relief in California Supreme Court from a lower court decision allowing non-California U.S. residents with working Shiley Convexo/Concave heart valves to litigate in California.
 In November 1991, the California Supreme Court held in the Stangvik case that non-U.S. residents could not pursue heart valve fracture claims in California courts. In November 1992, however, contrary to the California Supreme Court's ruling, the California Superior Court decided in the Alsup and Moore cases to allow non-California U.S. residents with working C/C valves to pursue their claims in California. At the same time, in the Retlzaff case, the court ruled that claims filed by foreign residents with properly functioning C/C valves should be litigated in their home countries.
 Believing that the trial court's decision in the Alsup and Moore cases is contrary to the principles of the Supreme Court's holding in the Stangvik decision, on Dec. 29 Pfizer filed an application for an extraordinary writ in the California Court of Appeal to correct it. The appellate court denied the writ on Dec. 30 without explanation. Pfizer will now seek relief from the state supreme court.
 Pfizer also believes that the claims filed by those with functioning C/C valves are baseless. In 29 decisions in 11 jurisdictions, including federal and state appellate decisions, courts have held that working valve cases seeking recovery for alleged anxiety claims are without merit.
 In the past year, Pfizer has negotiated a class action settlement with about 50,000 Shiley C/C heart valve recipients. The action, known as the Bowling settlement, has been judged fair, reasonable and equitable by a federal district court in Cincinnati. Approximately 850 C/C implantees chose to opt out of the Bowling class action. Of these, Pfizer settled about 330 claims in November 1992, leaving about 520 opt- outs. Of these, about 50 are California residents; about 225 are non- California U.S. residents; about 65 are foreign residents; and the residence of the remaining approximately 170 is unknown to Pfizer.
 -0- 1/6/93
 /CONTACT: A.A. Biesada, 212-573-2055, or Rick Honey, 212-573-2051, both of Pfizer/
 (PFE)


CO: Pfizer Inc ST: New York, California IN: MTC SU:

CK -- NY034 -- 2183 01/06/93 12:07 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 6, 1993
Words:385
Previous Article:TRANS FINANCIAL ANNOUNCES STOCK SPLIT
Next Article:UNITED AIRLINES ANNOUNCES MAJOR COST-REDUCTION PROGRAM TO ENSURE LONG-TERM FUTURE
Topics:


Related Articles
PFIZER RELEASES STATEMENT ON CALIFORNIA COURT OF APPEAL DECISION
PFIZER RESPONSE TO CALIFORNIA SUPERIOR COURT DECISION
PFIZER ANNOUNCES CALIFORNIA SUPREME COURT REVERSAL OF APPELLATE COURT DECISION IN HEART VALVE CASES
PFIZER SUCCESSFUL IN APPEALS FROM BOWLING CLASS-ACTION DECISION
PFIZER ANNOUNCES THAT SUPREME COURT DECLINES SHILEY HEART VALVE REVIEW
Court Rules in Favor of Pfizer in Trovan Trademark Suit.
Pfizer Statement on Viagra Use Patent Litigation in the United Kingdom.
U.S. Court of Appeals Affirms Pfizer's Six-Month Exclusivity for Diflucan.
Statement re Court Ruling.
California Court of Appeal Affirms Denial of Class Certification To Rezulin Plaintiffs.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters